The Nuclear Regulatory Commission accepted for review an application from Eden Radioisotopes LLC to construct a medical isotope production facility in Lea County, New Mexico on June 16, 2026. The facility would produce radioisotopes used in medical imaging and cancer treatment. The project includes a 1.8-megawatt thermal reactor to irradiate targets and a processing facility to extract and prepare the isotopes for medical use. A construction permit is required before operations can begin. Operational date source: Eden Radioisotopes LLC website, Timeline to Market section. The facility will primarily produce molybdenum-99 (Mo-99) and lutetium-177 (Lu-177), along with iodine-131 (I-131). The US currently lacks a reliable domestic source of Mo-99, which has a 66-hour half-life and cannot be stockpiled, relying instead on ageing reactors in South Africa, the Netherlands, and Belgium. The proposed reactor uses low-enriched uranium, optimised for high-yield isotope production, operating 22 hours per day with downtime used to replace targets. The construction permit application was originally filed May 8, 2026, with the NRC accepting it for review on June 16, 2026.